Impact of Endothelial and Leukocyte Senescence in Circulatory Shock States

Cardiovascular Diseases Clinical Trial

— Seneshock  

Official title:

Impact of Endothelial and Leukocyte Senescence in Circulatory Shock States

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03559569
• Other study ID #: 7031
• Status: Recruiting
• Start date: January 7, 2019
• Est. completion date: March 2025

Study information

• Verified date: August 2023
• Source: University Hospital, Strasbourg, France
• Contact: Morgane CLERC
• Phone: 03 88 11 68 55
• Email: morgane.clerc[@]chru-strasbourg.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Circulatory shocks (CS) are life-threatening, acute organ dysfunction. Advances in critical care medicine have decreased early hospital mortality, increasing the number of surviving patients. Regrettably, these survivors are at increased risk of new infections but also of cardiovascular disease. The investigators hypothesize that CS with multi-organ dysfunction is associated with premature senescence of endothelial cells and immune cells and promotes endothelial thrombogenicity and immunosenescence leading to cardiovascular disease and secondary infections. The aim of this work is therefore to evaluate the contribution of endothelial and leucocytes senescence to the occurrence of secondary events (infectious and cardiovascular) in patients with a CS. It will provide a better understanding of the pathogenesis of cardiovascular and immune diseases following a CS, likely to guide new management strategies to prevent their occurrence.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 520
• Est. completion date: March 2025
• Est. primary completion date: February 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

• Circulatory shock
• patient with health care insurance

Exclusion criteria:

• Patients' refusal to participate in clinical research
• Pregnant woman
• Breastfeeding woman
• A patient with a protective order

Related Conditions & MeSH terms

• Cardiovascular Diseases
• Infection
• Shock

Intervention

Biological:
• Biological samples will be done to evaluate the endothelial and leukocyte senescence.
Noninvasive, reproducible, and sensitive methods to measure cardiac function, endothelial function, and arterial stiffness will be assess.

Locations

Country	Name	City	State
France	Hôpitaux Universitaires de Strasbourg - Service de Réanimation médicale du NHC	Strasbourg

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Strasbourg, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The main criterion will be the acquisition of a senescent phenotype concerning leukocytes and endothelial cells.	Biological samples will be done to evaluate the endothelial and leukocyte senescence.	1 year
Secondary	Incidence of cardiovascular events and secondary infection in hospitalized patients in intensive care unit for circulatory shock states		5 years